Systemic chemotherapy is one of the remaining avenues available to an oncologist treating unresectable non-small cell lung cancer (NSCLC). Unfortunately, NSCLC indicated anticancer therapeutics do not provide significant patient survival benefits and have toxic side effects. These drugs will extend the time-to-progression of metastatic disease by small margins yet do little to decrease NSCLC mortality. An underlying theme to the current proposal is that one can obtain significant improvements in NSCLC chemotherapy with a more detailed molecular understanding of drug disposition and response. To obtain this understanding we will use a combination of structural biology and functional assays to study a human integral membrane protein directly linked to gemcitabine uptake within normal and neoplastic cells. The equilibrative nucleoside transporter (hENT) family is broadly distributed in human tissues, is known to transport a wide array of nucleoside antimetabolites, and is directly linked to chemotherapeutic outcomes. Specific goals we seek to address in this proposal include (1) determine the structure of hENT at atomic resolution, (2) develop in vitro functional assays using purified protein, and (3) characterize hENT functional determinants using three human lung cancer cell lines. Outcomes from these studies will be tuned to determine the molecular basis by which hENT regulatoin and transport of therapeutics occus. The broad vision is that these novel molecular insights can be advanced to clinical outcomes that guide treatment decisions in nucleoside based drug treatment of NSCLC.
These studies will investigate the function of a key membrane protein involved in drug response and disposition in the treatment of human cancer. Understanding how protein sequence and function for this protein relate to drug efficacy will provide a means by which to improve cancer chemotherapy and drug selection during treatment.
|Boswell-Casteel, Rebba C; Johnson, Jennifer M; Duggan, Kelli D et al. (2014) FUN26 (function unknown now 26) protein from saccharomyces cerevisiae is a broad selectivity, high affinity, nucleoside and nucleobase transporter. J Biol Chem 289:24440-51|
|Aravindan, Natarajan; Aravindan, Sheeja; Pandian, Vijayabaskar et al. (2014) Acquired tumor cell radiation resistance at the treatment site is mediated through radiation-orchestrated intercellular communication. Int J Radiat Oncol Biol Phys 88:677-85|
|Bio, Moses; Rajaputra, Pallavi; Nkepang, Gregory et al. (2014) Far-red light activatable, multifunctional prodrug for fluorescence optical imaging and combinational treatment. J Med Chem 57:3401-9|
|Janakiram, Naveena B; Mohammed, Altaf; Brewer, Misty et al. (2014) Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev Res (Phila) 7:300-9|
|Babu, Anish; Wang, Qi; Muralidharan, Ranganayaki et al. (2014) Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm 11:2720-33|
|Xiong, Xunhao; Arvizo, Rochelle R; Saha, Sounik et al. (2014) Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget 5:6453-65|
|Aravindan, S; Natarajan, M; Ramraj, S K et al. (2014) Abscopal effect of low-LET ýý-radiation mediated through Rel protein signal transduction in a mouse model of nontargeted radiation response. Cancer Gene Ther 21:54-9|
|VandenHeuvel, Katherine A; Carpentieri, David F; Chen, Jie et al. (2014) Ectomesenchymoma with embryonal rhabdomyosarcoma and ganglioneuroma, arising in association with benign triton tumor of the tongue. Pediatr Dev Pathol 17:226-30|
|Aravindan, Sheeja; Natarajan, Mohan; Herman, Terence S et al. (2013) Radiation-induced TNF* cross signaling-dependent nuclear import of NF*B favors metastasis in neuroblastoma. Clin Exp Metastasis 30:807-17|
|Chang, Theodore S; Lin, Hsueh-Kung; Rogers, Kyle A et al. (2013) Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung. Int J Clin Exp Pathol 6:2419-29|
Showing the most recent 10 out of 11 publications